Compare Stocks → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLPHNASDAQ:BNTCNASDAQ:HSTO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLPHBellerophon Therapeutics$0.06+1.7%$0.05$0.03▼$11.15$673K0.6760,636 shs10,136 shsBNTCBenitec Biopharma$6.83+1.6%$4.99$1.86▼$9.01$17.69M1.0366,825 shs10,272 shsHSTOHistogen$0.35$0.38$0.05▼$1.05$1.50M0.9217,945 shs6,956 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLPHBellerophon Therapeutics-7.68%-0.73%-9.68%-6.72%-99.25%BNTCBenitec Biopharma-2.04%+40.00%+33.33%+128.57%+79.76%HSTOHistogen+0.03%-29.98%-10.23%+3.76%-63.16%World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLPHBellerophon Therapeutics2.1437 of 5 stars3.00.00.04.83.20.00.6BNTCBenitec Biopharma1.5696 of 5 stars3.53.00.00.02.30.80.0HSTOHistogenN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLPHBellerophon Therapeutics2.00Hold$2.003,536.36% UpsideBNTCBenitec Biopharma3.00Buy$16.00134.26% UpsideHSTOHistogenN/AN/AN/AN/ACurrent Analyst RatingsLatest BLPH, BNTC, and HSTO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $16.002/15/2024BNTCBenitec BiopharmaJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $10.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLPHBellerophon TherapeuticsN/AN/AN/AN/A$0.27 per shareN/ABNTCBenitec Biopharma$80K221.12N/AN/A$0.12 per share56.92HSTOHistogen$3.77M0.40N/AN/A$3.13 per share0.11Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLPHBellerophon Therapeutics-$19.83M-$0.84N/A∞N/AN/A-187.35%-104.97%5/13/2024 (Estimated)BNTCBenitec Biopharma-$19.56MN/A0.00∞N/AN/A-204.34%-142.81%5/20/2024 (Estimated)HSTOHistogen-$10.62M-$2.81N/A∞N/A-65,142.11%-136.13%-90.87%N/ALatest BLPH, BNTC, and HSTO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/13/2024Q2 2024BNTCBenitec BiopharmaN/A-$2.64-$2.64-$2.64N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLPHBellerophon TherapeuticsN/AN/AN/AN/AN/ABNTCBenitec BiopharmaN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLPHBellerophon TherapeuticsN/A3.963.96BNTCBenitec Biopharma0.013.623.62HSTOHistogenN/A4.054.05OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLPHBellerophon Therapeutics10.61%BNTCBenitec Biopharma52.19%HSTOHistogenN/AInsider OwnershipCompanyInsider OwnershipBLPHBellerophon Therapeutics5.20%BNTCBenitec Biopharma4.30%HSTOHistogen3.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLPHBellerophon Therapeutics1812.23 million11.60 millionNo DataBNTCBenitec Biopharma182.59 million2.48 millionNo DataHSTOHistogen74.27 million4.13 millionNot OptionableBLPH, BNTC, and HSTO HeadlinesSourceHeadlineHistogen Inc: Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offeringfinanznachrichten.de - April 22 at 9:19 AMHistogen Files For Voluntary Chapter 11 Bankruptcy Protectionmarkets.businessinsider.com - April 18 at 11:31 PMHistogen files for Chapter 11, seeks liquidationmsn.com - April 18 at 6:31 PMHistogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offeringglobenewswire.com - April 18 at 5:29 PMHistogen Stock (OTC:HSTO) Dividends: History, Yield and Datesbenzinga.com - February 6 at 3:17 PMHistogen Announces Second Adjournment of Special Meeting of Stockholdersfinance.yahoo.com - December 14 at 6:46 PMHistogen Inc: Histogen Announces Adjournment of Special Meeting of Stockholdersfinanznachrichten.de - December 6 at 7:27 PMHistogen Announces Adjournment of Special Meeting of Stockholdersfinance.yahoo.com - December 5 at 6:26 PMHistogen Inc HSTOmorningstar.com - November 1 at 7:12 AMDays-to-cover ratio for HSTO surges to 4.25 due to rise in short interestknoxdaily.com - October 5 at 8:14 PMHSTO short interest fall by -56.24%, reflecting positive sentimentknoxdaily.com - September 21 at 3:17 PMWall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Ratesmsn.com - September 21 at 10:17 AMU.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.31%msn.com - September 20 at 6:11 PMHistogen Inc: Histogen Announces Board Approval of Complete Liquidation and Dissolutionfinanznachrichten.de - September 20 at 6:11 PMMagnet attracts $50M series A for efforts with molecular gluesbioworld.com - September 20 at 8:10 AMHistogen Board Approves To Dissolve And Wind Down Operationsmarkets.businessinsider.com - September 20 at 1:17 AMU.S. shares lower at close of trade; Dow Jones Industrial Average down 0.31%msn.com - September 19 at 8:16 PMBiotech firm Histogen to wind down after failing to raise capitalmsn.com - September 18 at 6:27 PMHistogen Announces Board Approval of Complete Liquidation and Dissolutionfinance.yahoo.com - September 18 at 6:27 PMHistogen views strategic alternativesthepharmaletter.com - July 7 at 9:13 AMHistogen shares are trading higher after the company decided to pause further development of its programs, commence exploring strategic alternatives.benzinga.com - July 6 at 7:06 PMHistogen plans to commence strategic alternatives processseekingalpha.com - July 5 at 7:16 PMHistogen to Explore Strategic Alternativesfinance.yahoo.com - July 5 at 7:16 PMAsia Pacific Alopecia Treatment Market to See Booming Worldwide ... - Digital Journalnews.google.com - May 13 at 8:35 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBellerophon TherapeuticsNASDAQ:BLPHBellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.Benitec BiopharmaNASDAQ:BNTCBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.HistogenNASDAQ:HSTOHistogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
